Skip to main content
. 2019 Aug 22;4(16):e122112. doi: 10.1172/jci.insight.122112

Figure 2. Adenosine A2b receptor is the major receptor in mediating inhibition of bladder smooth muscle purinergic contraction.

Figure 2

(A) Representative traces of bladder smooth muscle (BSM) purinergic contraction in response to electrical field stimulation (EFS) stimulation, which is insensitive to A2a receptor activation by CGS21680 (n = 7). (B) Representative traces of BSM purinergic contraction in response to EFS stimulation, which can be fully inhibited by A2b receptor activation by Bay 60-6583 (n = 13). (C) Representative traces of BSM contraction in response to α,β-meATP stimulation, which the CGS21680 pretreatment does not inhibit (n = 7). (D) Pretreatment with Bay 60-6583 inhibits α,β-meATP stimulated BSM contraction (n = 7). (E) Representative traces of BSM contraction in response to ADPβS stimulation, which CGS21680 pretreatment does not inhibit (n = 8). (F) Pretreatment with Bay 60-6583 inhibits ADPβS stimulated BSM contraction (n = 7). (G) quantitated data of A and B. (H) Quantitated data of C and D. (I) Quantitated data of E and F. (J) Dose-dependent inhibition by Bay 60-6583 on BSM purinergic contraction (atropine pretreatment) in response to EFS stimulation (n = 13). This inhibition is abolished in A2b-KO BSM as shown in K (n = 7). (L) Nonlinear regression of J and K.